ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for ...
Outlook Therapeutics (OTLK) has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. In her role as Vice ...
TipRanks on MSN
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK) 81.97% +33.92, ...
Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of ...
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: ...
The S&P 500 Dividend Aristocrats tracks companies in the index that have raised dividends every year for at least 25 straight ...
The core reason for the analyst's cautious posture stems from ongoing regulatory challenges. Intellia is navigating the aftermath of a clinical hold placed by the U.S. Food and Drug Administration ...
The Korea Development Bank (KDB) has forecast South Korea's economic growth rate for this year at 1.8%. This projection is in line with the estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback